top of page
Home
Calvine Healthcare
Calvine Sustainables
Equity Research
Basilea
Blog
Contact
Â
Use tab to navigate through the menu items.
All Posts
Search
Andrew Keith
Oct 2, 2023
FDA accepts ceftobiprole's NDA
Brian White
Sep 28, 2023
Key ceftobiprole data published
Andrew Keith
Sep 14, 2023
Basilea research report
Brian White
Aug 15, 2023
Basilea - H1 results and upgrade
Brian White
Aug 4, 2023
Basilea - ceftobiprole filed for US approval
Brian White
Jun 8, 2023
Basilea - Cresemba exceeding expectations
Brian White
Apr 18, 2023
Ceftobiprole delay a minor frustration
Brian White
Mar 23, 2023
Cresemba continues to deliver
Andrew Keith
Mar 15, 2023
Basilea's future in anti-infectives
Brian White
Feb 7, 2023
Another Cresemba Pfizer milestone
Brian White
Jan 11, 2023
Basilea - a year of significant achievement
Brian White
Jan 9, 2023
CHF20m Astellas milestone
Brian White
Dec 23, 2022
Basilea - Cresemba approved in Japan
Andrew Keith
Nov 9, 2022
Basilea - Sustainable profitability
Brian White
Nov 2, 2022
Basilea - Another oncology programme partnered
Brian White
Oct 24, 2022
Basilea - Positive data at IDweek
Brian White
Sep 20, 2022
Basilea - Still capturing value from oncology
Brian White
Sep 8, 2022
Basilea - Focus on anti-infectives apparent
Brian White
Sep 7, 2022
Basilea - Dilution overhang removed
Brian White
Aug 16, 2022
Basilea - H1 results show continued commercial and strategic progress
bottom of page
